Michael J Hall

List of Publications by Year
in descending order

54 papers	3,083 citations	361388 20 h-index	168376 53 g-index
55 all docs	55 docs citations	55 times ranked	5428 citing authors

#	Article	IF	Citations
1	Changes in Burnout Among Oncology Physician Assistants Between 2015 and 2019. JCO Oncology Practice, 2022, 18, e47-e59.	2.9	10
2	Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. Oncogene, 2022, 41, 260-267.	5.9	7
3	Risk assessment and genetic counseling for Lynch syndrome â€“ Practice resource of the National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. Journal of Genetic Counseling, 2022, 31, 568-583.	1.6	7
4	Association of Organizational Context, Collaborative Practice Models, and Burnout Among Physician Assistants in Oncology. JCO Oncology Practice, 2022, , OP2100627.	2.9	7
5	Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology. Cancer Treatment Reviews, 2022, 104, 102337.	7.7	6
6	The Role of Medical Mistrust in Concerns about Tumor Genomic Profiling among Black and African American Cancer Patients. International Journal of Environmental Research and Public Health, 2022, 19, 2598.	2.6	6
7	Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 2022, 40, 3929-3939.	1.6	66
8	Pathologic Complete Response in Patient With ATM Mutation After Neoadjuvant FOLFOXIRI Plus Panitumumab Therapy for Locally Advanced Colon Cancer: A Case Report. Clinical Colorectal Cancer, 2021, 20, e96-e99.	2.3	5
9	Clinical Validation of a Machine-learningâ€“derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. Clinical Cancer Research, 2021, 27, 1174-1183.	7.0	28
10	Pancreatic cancer in the era of COVID-19 pandemic: Which one is the lesser of two evils?. World Journal of Clinical Oncology, 2021, 12, 54-60.	2.3	10
11	Psychological distress in patients with metastatic cancer enrolling on phase I clinical trials. Journal of Cancer Survivorship, 2021, 15, 398-402.	2.9	4
12	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. Clinical Cancer Research, 2021, 27, 3234-3242.	7.0	24
13	NovelLRRK2mutations and other rare, non-BAP1-related candidate tumor predisposition gene variants in high-risk cancer families with mesothelioma and other tumors. Human Molecular Genetics, 2021, 30, 1750-1761.	2.9	7
14	Oncologistsâ€™ Perceptions of Tumor Genomic Profiling and the Communication of Test Results and Risks. Public Health Genomics, 2021, 24, 304-309.	1.0	6
15	Expanding Germline Testing to All Patients With Esophagogastric Cancersâ€”Easy to Do, Harder to Justify. JAMA Network Open, 2021, 4, e2114789.	5.9	1
16	Cascade Genetic Testing for Hereditary Cancer Risk: An Underutilized Tool for Cancer Prevention. JCO Precision Oncology, 2021, 5, 1387-1396.	3.0	23
17	Patients' Expectations of Benefits From Large-Panel Genomic Tumor Testing in Rural Community Oncology Practices. JCO Precision Oncology, 2021, 5, 1554-1562.	3.0	4
18	Germline Pathogenic Variants in the Ataxia Telangiectasia Mutated (ATM) Gene are Associated with High and Moderate Risks for Multiple Cancers. Cancer Prevention Research, 2021, 14, 433-440.	1.5	68

#	Article	IF	Citations
19	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. Npj Precision Oncology, 2021, 5, 95.	5.4	9
20	Updates in Chemoprevention Research for Hereditary Gastrointestinal and Polyposis Syndromes. Current Treatment Options in Gastroenterology, 2021, 19, 30-46.	0.8	2
21	X- and Y-Linked Chromatin-Modifying Genes as Regulators of Sex-Specific Cancer Incidence and Prognosis. Clinical Cancer Research, 2020, 26, 5567-5578.	7.0	33
22	Longitudinal follow-up after telephone disclosure in the randomized COGENT study. Genetics in Medicine, 2020, 22, 1401-1406.	2.4	4
23	Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position statement on multigene panel testing for patients with colorectal cancer and/or polyposis. Familial Cancer, 2020, 19, 223-239.	1.9	39
24	Impact of Baseline Nutrition and Exercise Status on Toxicity and Outcomes in Phase I and II Oncology Clinical Trial Participants. Oncologist, 2020, 25, 161-169.	3.7	26
25	A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instabilityâ€“High Cases in 67,000 Patient Samples. Journal of Molecular Diagnostics, 2019, 21, 1053-1066.	2.8	147
26	Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. New England Journal of Medicine, 2019, 381, 317-327.	27.0	1,521
27	Disease-Associated Genetic Variation in Human Mitochondrial Protein Import. American Journal of Human Genetics, 2019, 104, 784-801.	6.2	21
28	Preferences for inâ€person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study. Clinical Genetics, 2019, 95, 293-301.	2.0	16
29	Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results. Journal of the National Cancer Institute, 2018, 110, 985-993.	6.3	35
30	Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOGâ€ACRIN Cancer Research Group (E4203). Cancer, 2018, 124, 688-697.	4.1	6
31	Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults. JAMA Oncology, 2018, 4, e173580.	7.1	66
32	TumorNext-Lynch-MMR: a comprehensive next generation sequencing assay for the detection of germline and somatic mutations in genes associated with mismatch repair deficiency and Lynch syndrome. Oncotarget, 2018, 9, 20304-20322.	1.8	23
33	Multigene Panel Testing and Breast Cancer Risk. JAMA Oncology, 2017, 3, 1176.	7.1	8
34	Functional analysis of rare variants in mismatch repair proteins augments results from computation-based predictive methods. Cancer Biology and Therapy, 2017, 18, 519-533.	3.4	21
35	Randomized Controlled Trials in Hereditary Cancer Syndromes. Surgical Oncology Clinics of North America, 2017, 26, 729-750.	1.5	3
36	Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women. JCO Precision Oncology, 2017, 1, 1-12.	3.0	96

#	Article	IF	Citations
37	Understanding patient and provider perceptions and expectations of genomic medicine. Journal of Surgical Oncology, 2015, 111, 9-17.	1.7	27
38	Bilateral granulosa cell tumors: a novel malignant manifestation of multiple endocrine neoplasia 1 syndrome found in a patient with a rare menin in-frame deletion. The Application of Clinical Genetics, 2015, 8, 69.	3.0	5
39	Genetic Variants That Predispose to DNA Double-Strand Breaks in Lymphocytes From a Subset of Patients With Familial Colorectal Carcinomas. Gastroenterology, 2015, 149, 1872-1883.e9.	1.3	31
40	Germline variants in cancer risk genes detected by NGS-based comprehensive tumor genomic profiling (CGP).. Journal of Clinical Oncology, 2015, 33, 11084-11084.	1.6	5
41	Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer. Radiotherapy and Oncology, 2014, 113, 35-40.	0.6	13
42	Direct-to-patient disclosure of results of mismatch repair screening for Lynch syndrome via electronic personal health record: a feasibility study. Genetics in Medicine, 2014, 16, 854-861.	2.4	14
43	Gene Panel Testing for Inherited Cancer Risk. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1339-1346.	4.9	122
44	Incorporating genomic testing using next-generation sequencing (NGS) into clinical practice: Genetic counselorsâ€™ (GC) experience, knowledge, and perceived competence.. Journal of Clinical Oncology, 2014, 32, e17624-e17624.	1.6	1
45	Academic (AO) and community (CO) oncologistsâ€™ knowledge, understanding, and preparedness for clinical next-generation sequencing genomic testing (NGSGT).. Journal of Clinical Oncology, 2014, 32, e17635-e17635.	1.6	4
46	Predictors of patient uptake of colorectal cancer gene environment risk assessment. Genome Medicine, 2012, 4, 92.	8.2	10
47	Effects of a Decision Support Intervention on Decisional Conflict Associated with Microsatellite Instability Testing. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 249-254.	2.5	24
48	Counterpoint: Implementing Population Genetic Screening for Lynch Syndrome Among Newly Diagnosed Colorectal Cancer Patientsâ€”Will the Ends Justify the Means?. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 606-611.	4.9	33
49	Prevalence of BRCA1 and BRCA2 Mutations in Women with Breast Carcinoma In Situ and Referred for Genetic Testing. Cancer Prevention Research, 2010, 3, 1579-1585.	1.5	21
50	Barriers to participation in cancer prevention clinical trials. Acta OncolÃ³gica, 2010, 49, 757-766.	1.8	18
51	BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breastâ€ovarian cancer. Cancer, 2009, 115, 2222-2233.	4.1	305
52	Single nucleotide polymorphisms and colorectal neoplasia risk: Updates and impact. Current Colorectal Cancer Reports, 2009, 5, 15-23.	0.5	1
53	Influence of Race/Ethnicity on Genetic Counseling and Testing for Hereditary Breast and Ovarian Cancer. Breast Journal, 2009, 15, S56-S62.	1.0	83
54	T2047 Gene-Gene Interactions and the Risk of Colorectal Neoplasia Is Associated with Variants of the APC and CD24 Genes. Gastroenterology, 2008, 134, A-607-A-608.	1.3	1